Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 7/20 | 0.39 |
| ▸ | PPARG | P37231 | 5/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537919 | 0.92 | PLA2G2A (0.40) | PPARDFFAR1PLA2G2APLA2G10PPARA | |
| SCHEMBL3762522 | 0.92 | PLA2G2A (0.41) | PPARDFFAR1PLA2G2APLA2G10PPARA | |
| SCHEMBL3539539 | 0.88 | PPARD (0.45) | PPARDFFAR1PLA2G2APLA2G10PPARA | |
| SCHEMBL3777497 | 0.88 | PPARD (0.45) | PPARDFFAR1PPARAPPARGCHRM5 | |
| SCHEMBL3769064 | 0.85 | PPARD (0.47) | PPARDFFAR1PPARAPPARGCHRM5 | |
| SCHEMBL3768982 | 0.85 | PPARD (0.46) | PPARDFFAR1PPARAPPARGCHRM5 | |
| SCHEMBL3769208 | 0.85 | PPARD (0.46) | PPARDFFAR1PPARAPPARGCHRM5 | |
| SCHEMBL3770849 | 0.84 | PPARD (0.40) | PPARDFFAR1PLA2G2APPARAPPARG | |
| SCHEMBL3529390 | 0.84 | PLA2G2A (0.37) | PPARDPLA2G2APLA2G10PPARAPPARG | |
| SCHEMBL13341993 | 0.84 | PLA2G2A (0.41) | PPARDFFAR1PLA2G2APLA2G10PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934206-B1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| EP-1934206-B1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1934206-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | PPARD, PPARA, PPARG | PPARD 1/4885FFAR1 24/4885PLA2G2A 1341/4885 |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | PPARD, PPARA, PPARG | PPARD 1/4885FFAR1 12/4885PLA2G2A 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.